JAMES HAROLD: Open Payments
NPI 1760543482 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,737 in 246 payments from 18 companies in 2025. Trend: 2023 $30,126 · 2024 $1,183 · 2025 $5,737
Food & beverage: $5,617Education: $120
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 34 | $820 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $710 |
| ABBVIE INC. | 45 | $685 |
| Neurocrine BioSciences, Inc. | 20 | $656 |
| Teva Pharmaceuticals USA, Inc. | 17 | $600 |
| Axsome Therapeutics, Inc. | 22 | $551 |
| Janssen Pharmaceuticals, Inc | 10 | $329 |
| E.R. Squibb & Sons, L.L.C. | 10 | $255 |
| Alkermes, Inc. | 11 | $247 |
| Vanda Pharmaceuticals Inc. | 14 | $237 |
Products named: REXULTI, CAPLYTA, VRAYLAR, INGREZZA, Auvelity, AUSTEDO XR, COBENFY, INVEGA SUSTENNA.
Industry payments across TX — which companies pay providers there.
